<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04606602</url>
  </required_header>
  <id_info>
    <org_study_id>SLN360-001</org_study_id>
    <nct_id>NCT04606602</nct_id>
  </id_info>
  <brief_title>Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)</brief_title>
  <official_title>A Randomised, Double-blind, Placebo Controlled, First-in-human Study to Investigate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of SLN360 in Subjects With Elevated Lipoprotein(a)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Silence Therapeutics plc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Silence Therapeutics plc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety and tolerability of SLN360 in patients with elevated&#xD;
      Lp(a).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This first-in-human (FIH) study will investigate the safety, tolerability, pharmacokinetics&#xD;
      (PK) and pharmacodynamics (PD) of SLN360 after single ascending s.c. doses and multiple doses&#xD;
      in healthy male and female subjects.&#xD;
&#xD;
      Up to 9 cohorts of 88 patients with elevated Lp(a) will be enrolled. Each patient will&#xD;
      receive single or multiple doses of SLN360 or placebo given by subcutaneous (s.c) injection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Day 150</time_frame>
    <description>safety and tolerability will be reported separately following single-dose administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Day 201</time_frame>
    <description>safety and tolerability will be reported separately following multiple-dose administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: peak plasma concentration (Cmax)</measure>
    <time_frame>Day 150 and Day 201</time_frame>
    <description>safety and tolerability will be reported separately following single-dose and multiple-dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: area under the plasma concentration (AUC)</measure>
    <time_frame>Day 150 and Day 201</time_frame>
    <description>safety and tolerability will be reported separately following single-dose and multiple-dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: apparent total clearance from plasma after s.c injection (CL/F)</measure>
    <time_frame>Day 150 and Day 201</time_frame>
    <description>safety and tolerability will be reported separately following single-dose and multiple-dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic: Change in Lp(a)</measure>
    <time_frame>Day 150 and Day 201</time_frame>
    <description>safety and tolerability will be reported separately following single-dose and multiple-dose administration.</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Hyperlipidemias</condition>
  <condition>Dyslipidemias</condition>
  <condition>Elevated Lp(a)</condition>
  <arm_group>
    <arm_group_label>30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>900 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg multi dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg multi dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>300 mg multi dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>600 mg multi dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo multi dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SLN360</intervention_name>
    <description>SLN360 for subcutaneous (s.c.) injection</description>
    <arm_group_label>100 mg</arm_group_label>
    <arm_group_label>100 mg multi dose</arm_group_label>
    <arm_group_label>200 mg multi dose</arm_group_label>
    <arm_group_label>30 mg</arm_group_label>
    <arm_group_label>300 mg</arm_group_label>
    <arm_group_label>300 mg multi dose</arm_group_label>
    <arm_group_label>600 mg</arm_group_label>
    <arm_group_label>600 mg multi dose</arm_group_label>
    <arm_group_label>900 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sodium chloride for subcutaneous (s.c.) injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Placebo multi dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Elevated plasma Lp(a) ≥ 150nmol/L.&#xD;
&#xD;
          -  All subjects must agree to adhere to appropriate contraception requirements.&#xD;
&#xD;
          -  Subjects must provide written informed consent and be able to comply with all study&#xD;
             requirements.&#xD;
&#xD;
          -  Body mass index of ≥ 18 kg/m2 and ≤ 45 kg/m2.&#xD;
&#xD;
          -  For the MD part: confirmed history of stable atherosclerortic cardiovascular disease.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Single Ascending Dose only: any history of clinically overt cardiovascular disease,&#xD;
             defined as acute coronary syndromes, myocardial infarction, stable angina, coronary or&#xD;
             other revascularization, ischemic stroke or transient ischemic attack and&#xD;
             atherosclerotic peripheral arterial disease.&#xD;
&#xD;
          -  Multiple Dose only: recent history of acute cardiovascular disease events within 6&#xD;
             months of screening (including, but not limited to, acute myocardial infarction,&#xD;
             unstable angina, acute stroke and acute limb ischemia).&#xD;
&#xD;
          -  Moderate or severe hepatic cirrhosis with Child-Pugh grade B or C, or other current or&#xD;
             previous liver disease.&#xD;
&#xD;
          -  Active serious mental illness or psychiatric disorder, including but not limited to&#xD;
             schizophrenia, bipolar disorder, or severe depression requiring current&#xD;
             pharmacological intervention.&#xD;
&#xD;
          -  Any conditions which, in the opinion of the Investigator, would make the subject&#xD;
             unsuitable for enrolment in the study or could interfere with the subject's&#xD;
             participation in, or completion of the study.&#xD;
&#xD;
          -  Subjects with previous or current use of medication or therapies significantly&#xD;
             affecting Lp(a) level or hormone replacement therapy, unless on a stable dose for ≥ 8&#xD;
             weeks prior to screening&#xD;
&#xD;
          -  History or clinical evidence of alcohol or illegal drug misuse within the 6 months&#xD;
             before screening.&#xD;
&#xD;
          -  History of multiple drug allergies or history of allergic reaction to an&#xD;
             oligonucleotide or GalNAc, or intolerance to s.c. injections.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sanjay Patel</last_name>
    <phone>+44 20 3457 6900</phone>
    <email>s.patel@silence-therapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Silence Therapeutics</last_name>
    <email>patient-info@silence-therapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research Ltd.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Metabolic and Atherosclerosis Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>216-444-9968</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Amsterdam Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hammersmith Medicines Research</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Imperial College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 7, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyslipidemia, Dyslipoproteinemia, Hyperlipidemia, Hyperlipoproteinemia, Hyperlipoproteinemia (a), Lipoprotein, Lipoprotein (a)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

